1. Scrip
  2. >>Drug Pricing

UK Experimental AMR Payment Program “On Track”

Two Antibiotics To Be Identified For Assessment By Year-End

 
• By Sten Stovall

Designers of the UK’s experimental antibiotic payment system aim to identify two drugs later this year which will then undergo a novel technology assessment in 2021.

Incentives_Magnet
UK trials world's first ‘subscription’ payment model for novel antibiotics • Source: Shutterstock

Health authorities in the UK remain on track with their program for testing a "pull" reward incentive mechanism as a way to both ensure adequate supply of antibiotics - a drug class that is fast ebbing away – while stimulating innovation for new antimicrobial drugs, a process that will also use health technology evaluations of the added value from any new antimicrobial, one of the project’s team leaders told Scrip.

The AMR ‘develop and test’ program, which first launched last summer, seeks to find a balance between supply and demand...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

Medicare Price Cuts For 15 Drugs In 2027 Likely Not As Large As CMS Estimates

 
• By Mandy Jackson

Under the Inflation Reduction Act, CMS negotiated lower Medicare Part D prices for 15 drugs with 2027 costs 38%-85% lower than 2024 list prices, but analyses of net prices paid last year show smaller discounts.

Medicare Negotiations 2.0 Slash Prices Up To 85%, But Mean Cuts Barely Budge

 
• By Manas Mishra

The second cycle of IRA price negotiations could result in price cuts as high as 85% to the 2024 list prices, but the mean discount across the 15 negotiated drugs appears similar to the previous round.

Itvisma Broad Label A Big Boon For Novartis’s SMA Revenues

 
• By Kevin Grogan

US FDA approval of the intrathecal formulation of Zolgensma means many more patients with spinal muscular atrophy will be eligible for the gene therapy.

Arrowhead’s Redemplo Approval Sets Up Standoff With Ionis’s Tryngolza

 
• By Jessica Merrill

Redemplo is Arrowhead’s first commercial product, and the drug will enter a competitive market. Arrowhead and Ionis have taken different pricing paths, however.

More from Scrip

Pipeline Watch: Eight Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Sibeprenlimab’s US Accelerated Approval Drives IgAN Competition Forward

 
• By Lisa Takagi

Following US approval of its first-in-class drug for IgAN sibeprelimab, Otsuka is planning an sNDA for an autoinjector in 2026 and is in talks with regulatory authorities in Japan and Europe.

The Rise of China Biopharma – Five Themes In 2025

 
• By Andrew McConaghie

The growth of China’s biopharma sector has been perhaps the most significant sector trend this year – Scrip outlines five themes that have emerged during 2025 and in discussions at the recent Jefferies conference in London.